Terms: = Prostate cancer AND SND1, Q7KZF4, TDRD11, p100, ENSG00000197157, 27044 AND Clinical Outcome
1 results:
1. MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer.
Fenor MD; Ruiz-Llorente S; Rodríguez-Moreno JF; Caleiras E; Torrego JC; Sevillano-Fernández E; Navarro P; Yagüe-Fernández M; Amarilla-Quintana S; Barquín A; García-Donas J
Clin Transl Oncol; 2022 Dec; 24(12):2432-2440. PubMed ID: 35994225
[TBL] [Abstract] [Full Text] [Related]
